Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 20/20 | 0.73 |
| ▸ | CXCR1 | P25024 | 14/20 | 0.66 |
| ▸ | CCR7 | P32248 | 4/20 | 0.65 |
| ▸ | CCR6 | P51684 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20865603 | 0.90 | CXCR2 (0.73) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL1682706 | 0.88 | CXCR2 (0.64) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL247336 | 0.84 | CXCR2 (0.74) | CXCR2CXCR1CCR6 | |
| SCHEMBL247335 | 0.84 | CXCR2 (1.00) | CXCR2CXCR1CCR6 | |
| SCHEMBL18870051 | 0.82 | CXCR2 (0.66) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL12262726 | 0.82 | CXCR2 (0.68) | CXCR2CXCR1CCR6 | |
| SCHEMBL13076091 | 0.82 | CXCR2 (0.66) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL12262212 | 0.81 | CXCR2 (1.00) | CXCR2CXCR1CCR6 | |
| SCHEMBL14319674 | 0.81 | CXCR2 (0.64) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL14450094 | 0.81 | CXCR2 (0.78) | CXCR2CXCR1CCR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019067332-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH A COMBINATION OF PROGRAMMED DEATH RECEPTOR (PD-1) ANTIBODIES AND A CXCR2 ANTAGONIST | MERCK SHARP & DOHME CORP. (US) | 2019-04-04 | — | — | WO | disclosed |
| EP-2178826-B1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF 1,2-SUBSTITUTED 3,4-DIOXO-1-CYCLOBUTENE COMPOUNDS | MERCK SHARP & DOHME (US) | 2017-05-17 | — | — | EP | disclosed |
| EP-2168956-B1 | Synthesis of 2-Hydroxy-N,N-Dimethyl-3-[[2-[1(r) - (5-Methyl-2-Furanyl) Propyl] -3, 4-Dioxo-1-Cyclobuten-1-Yl]amino] Benzamide | MERCK SHARP & DOHME (US) | 2013-03-20 | — | — | EP | disclosed |
| US-20070155756-A1 | Treatment of chemokine mediated diseases | SCHERING CORPORATION | 2007-07-05 | — | — | US | disclosed |
| US-20070155756-A1 | Treatment of chemokine mediated diseases | SCHERING CORPORATION | 2007-07-05 | — | — | US | disclosed |
| EP-1381590-B1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | SCHERING CORP (US) | 2007-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155756-A1 | Treatment of chemokine mediated diseases | CXCR3, ACKR3, CCL11 | CXCR2 6/4885CXCR1 5/4885CCR7 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.